000 | 04138naaaa2200889uu 4500 | ||
---|---|---|---|
001 | https://directory.doabooks.org/handle/20.500.12854/69300 | ||
005 | 20220714185655.0 | ||
020 | _abooks978-3-03943-490-9 | ||
020 | _a9783039434893 | ||
020 | _a9783039434909 | ||
024 | 7 |
_a10.3390/books978-3-03943-490-9 _cdoi |
|
041 | 0 | _aEnglish | |
042 | _adc | ||
072 | 7 |
_aM _2bicssc |
|
100 | 1 |
_aHirbe, Angela C. _4edt _91608912 |
|
700 | 1 |
_aPratilas, Christine A. _4edt _91608913 |
|
700 | 1 |
_aDodd, Rebecca D. _4edt _91608914 |
|
700 | 1 |
_aHirbe, Angela C. _4oth _91608912 |
|
700 | 1 |
_aPratilas, Christine A. _4oth _91608913 |
|
700 | 1 |
_aDodd, Rebecca D. _4oth _91608914 |
|
245 | 1 | 0 | _aGenomics and Models of Nerve Sheath Tumors |
260 |
_aBasel, Switzerland _bMDPI - Multidisciplinary Digital Publishing Institute _c2020 |
||
300 | _a1 electronic resource (172 p.) | ||
506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
520 | _aNerve sheath tumors can be a significant cause of morbidity for many patients. These include benign tumors such as schwannomas, diffuse and plexiform neurofibromas, and atypical neurofibromas, as well as the aggressive soft tissue sarcoma known as the malignant peripheral nerve sheath tumor (MPNST). Nerve sheath tumors occur sporadically and in the context of the clinical neuro-genetic tumor predisposition syndromes neurofibromatosis type 1 (NF1) and type 2 (NF2). Historically, the mainstay of treatment for nerve sheath tumors has been surgery. However, for both benign and malignant nerve sheath tumors, there is a high recurrence rate, highlighting the pressing need for novel therapies. As we have entered the genomic era, the hope is that an improved understanding of the genetics, and therefore the biology, of these tumors will ultimately lead to therapies that result in better outcomes. In this Special Issue, we include both review articles and original research related to the genomic understanding and modeling of schwannomas, plexiform and diffuse neurofibromas, atypical neurofibromas, and malignant peripheral nerve sheath tumors as well as genomic methods being developed and applied to advance our understanding of these tumors. | ||
540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by/4.0/ _2cc _4https://creativecommons.org/licenses/by/4.0/ |
||
546 | _aEnglish | ||
650 | 7 |
_aMedicine _2bicssc |
|
653 | _aneurofibromatosis type 1 | ||
653 | _anerve sheath tumor | ||
653 | _acancer | ||
653 | _alatent variables | ||
653 | _amachine learning | ||
653 | _asupervised learning | ||
653 | _atransfer learning | ||
653 | _arandom forest | ||
653 | _ametaVIPER | ||
653 | _atumor deconvolution | ||
653 | _aneurofibromatosis | ||
653 | _amalignant peripheral nerve sheath tumor | ||
653 | _aMPNST | ||
653 | _apolycomb repressive complex | ||
653 | _aPRC2 | ||
653 | _aNF1 | ||
653 | _akinase | ||
653 | _akinome adaptation | ||
653 | _akinome reprogramming | ||
653 | _aMET | ||
653 | _aMEK | ||
653 | _adoxorubicin | ||
653 | _acapmatinib | ||
653 | _atram | ||
653 | _agenomics | ||
653 | _atumor evolution | ||
653 | _apathology | ||
653 | _anext generation sequencing | ||
653 | _aclinical genetics | ||
653 | _amalignant peripheral nerve sheath tumors | ||
653 | _aplexiform neurofibromas | ||
653 | _aSchwann cells | ||
653 | _aneurofibromatosis type 1 syndrome | ||
653 | _aneurofibromin 1 | ||
653 | _agenetically engineered mouse models | ||
653 | _aheterogeneity | ||
653 | _aCRISPR/Cas9 | ||
653 | _amouse models | ||
653 | _asarcoma | ||
653 | _atumor microenvironment | ||
653 | _aneurofibromatosis 1 (NF1) | ||
653 | _amebendazole (MBZ) | ||
653 | _aCOX-2 inhibitor | ||
653 | _amalignancy | ||
653 | _achemoprevention | ||
653 | _anerve sheath tumors | ||
856 | 4 | 0 |
_awww.oapen.org _uhttps://mdpi.com/books/pdfview/book/3090 _70 _zDOAB: download the publication |
856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/69300 _70 _zDOAB: description of the publication |
999 |
_c3008914 _d3008914 |